Obtainable in pharmacies, Mallya is suitable with most disposable insulin pens1
Sufferers have a digital answer to precisely2 and safely monitor their day-to-day therapy
BIOCORP (Paris:ALCOR) (FR0012788065 – ALCOR / Eligible PEA PME) , a French firm specialised within the design, improvement and manufacturing of progressive medical gadgets, and Roche Diabetes Care France, a reference firm within the help of sufferers with diabetes, announce the launch in France of Mallya, a medical machine out there in pharmacies. Developed by BIOCORP, this good insulin pen machine collects and transfers insulin knowledge with close to 100% accuracy2. Rechargeable by way of its USB port, Mallya is suitable with most disposable insulin pens1. This innovation goals to simplify the every day lifetime of sufferers with diabetes present process insulin remedy, and will assist keep away from errors or oversights.
Healthcare corporations BIOCORP and Roche Diabetes Care France are finalizing their collaboration – introduced final June – with the distribution of Mallya good gadgets for insulin injection pens because the starting of April. Manufactured in Clermont-Ferrand (France), this innovation for sufferers taking insulin is the primary in its class to obtain the CE-mark (medical machine).
Reusable and suitable with 91%1 of disposable insulin pens, Mallya robotically collects insulin knowledge (dose, date, time) and transfers it to the Gluci-Chek software developed by Roche Diabetes Care France, guaranteeing certified info on which the affected person can rely and the doctor can then make selections3. With integration into the Roche Diabetes Care France digital ecosystem, sufferers profit from options that lighten the psychological burden of their illness, in a context the place greater than 750,000 folks4 are handled with insulin injections in France (excluding insulin pumps).
“The industrial launch of Mallya represents an essential milestone for BIOCORP. We’re actually proud to be main it with Roche Diabetes Care France. Its main place, its huge distribution community in pharmacies and the connection of our progressive machine to its Gluci-Chek answer current simple advantages for all healthcare professionals but additionally and above all for diabetic sufferers on the lookout for a greater high quality of life, a greater consolation within the administration and every day follow-up of their illness”, mentioned Eric Dessertenne, CEO of BIOCORP.
“For greater than 40 years, we now have been serving to folks with diabetes assume much less concerning the day-to-day administration of their illness. We’re dedicated to the autonomy and high quality of lifetime of sufferers with diabetes, empowering them to know and act on their situation. That is exactly what Mallya permits, when built-in with our digital ecosystem for sufferers and healthcare professionals. We’re at the moment the one firm to supply a top quality answer based mostly on a CE marked medical machine”, added Frédéric Jacquey, President of Roche Diabetes Care France.
An innovation to enhance the every day life and monitoring of diabetic sufferers on insulin
After the creation of insulin for therapeutic functions 100 years in the past, innovation continues within the subject of diabetes, with the identical ambition: to allow an increasing number of sufferers to dwell higher with their diabetes each day, a powerful problem for sufferers handled with insulin. To this finish, Mallya collects and transfers insulin knowledge in actual time5 to their smartphone.
As soon as the machine is put in, the affected person selects and injects his or her insulin models as common, with knowledge switch (date, time, chosen dose) being performed robotically. Whereas 37%6 of sufferers with diabetes felt extra anxious about their situation through the first Covid19 confinement, the straightforward and correct2 Mallya machine makes it simpler for them to comply with the evolution of their illness. It may thus contribute to extra serenity, extra safety and fewer error or forgetfulness in taking their therapy.
Shared with healthcare professionals3 by means of the devoted Roche Diabetes Care Platform, correct and complete insulin knowledge2 permits them to observe – face-to-face or remotely – the progress of their sufferers’ illness, refine their interpretation and assist alter therapy selections.
A tool built-in into a worldwide answer to facilitate diabetes administration
The machine enhances Roche Diabetes Care France’s digital ecosystem for built-in personalised diabetes administration. This answer was beforehand based mostly on three parts: related blood glucose meters (Accu-Chek® Cell, Accu-Chek® Information), the Gluci-Chek software and the Roche Diabetes Care platform devoted to healthcare professionals. Mallya is including insulin knowledge for extra complete affected person monitoring.
Used usually by greater than 60,000 diabetic sufferers in France, this smartphone software combines three main functionalities for personalised diabetes administration: a carbohydrate calculation software with a visualization of the parts on the plate, a self-monitoring of blood glucose diary and a graphic visualization of glycemic outcomes.
As soon as Mallya is related to Gluci-Chek, the affected person now not has to manually report his or her insulin doses, as the information is robotically displayed within the affected person’s blood glucose logbook, for any suitable insulin pen1. In a context the place French persons are confined once more and the place 58%3 of sufferers with diabetes didn’t really feel they’d obtained any explicit assist throughout their first confinement, this related machine can present actual shut monitoring.
ABOUT ROCHE DIABETES CARE FRANCE
Roche Diabetes Care is a healthcare firm specializing in diabetes. For greater than 40 years, it has been pioneering options to fulfill the wants of sufferers and healthcare professionals: medical gadgets (blood glucose meters, auto-pickers, insulin pumps), digital options (functions, platform for sharing blood glucose knowledge between sufferers and healthcare professionals) and providers (info and therapeutic training help). By the implementation of a worldwide answer connecting medical gadgets and digital options, Roche Diabetes Care is paving the best way for built-in Customized Diabetes Administration (iPDM), with the intention of facilitating and optimizing the administration and monitoring of this advanced illness.
Roche Diabetes Care France is a subsidiary of the Roche Group in France, alongside Roche SAS France and Roche Diagnostics France. For extra info, please go to www.roche.fr.
Acknowledged for its experience within the improvement and manufacture of medical gadgets and supply programs, BIOCORP has at the moment acquired a number one place within the related medical machine market due to Mallya. This good sensor for insulin injection pens permits dependable monitoring of injected doses and thus provides higher compliance within the therapy of sufferers with diabetes. Obtainable on the market from 2020, Mallya spearheads BIOCORP’s product portfolio of progressive related options. The corporate has 70 staff. BIOCORP is listed on Euronext since July 2015 (FR0012788065 – ALCOR). For extra info, please go to www.biocorpsys.com.
1 The Mallya medical machine is suitable with Solostar pens (ref. 9828648001), FlexPen pens (ref. 9832360001) and KwikPen pens (ref. 9827587001) aside from Junior KwikPen pens as of January 1, 2021. Calculation of market share for disposable insulin pens from Caisse Nationale d’Assurance Maladie. Open Medic 2019 database.
2 99% in line with Mallya IFU model 6. Warning: some exterior components might have an effect on the accuracy of dose measurement or knowledge switch.
3 If the affected person decides to share his/her knowledge.
4 Supply: IQVIA – LTD : Evaluation of BGMin actual life – Meters and strips markets – CMA February 2020 – Sufferers and quantity.
5 As quickly as Bluetooth is activated.
6 On-line examine carried out by CSA Analysis for Roche Diabetes Care France from Might 18th to twenty seventh, 2020, with 504 diabetic sufferers (101 type1 diabetic sufferers and 403 type2 diabetic sufferers)
View supply model on businesswire.com: https://www.businesswire.com/news/home/20210412005837/en/
Chairman of the Board
Chief Govt Officer
Advertising & Communication Director
+ 33 (0)6 88 69 72 85
+33 (0)6 87 88 46 26
+33 (0)6 63 66 59 22
ROCHE DIABETES CARE FRANCE
+33 (0)6 45 87 46 51
+33 (0)7 78 38 09 12